Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22

Rhea-AI Summary

Glaukos Corporation (NYSE: GKOS) will announce its fourth quarter and full year 2022 financial results after market close on February 22, 2023. The company's management will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss these results. The event aims to provide insights into the company's performance, particularly in the ophthalmic medical technology sector, highlighting its ongoing commitment to innovation in glaucoma and corneal disorder treatments.

Investors can access the live webcast via Glaukos' investor relations website.

Positive

• Scheduled announcement of Q4 and full year 2022 financial results, which may provide key insights into financial health.
• Management's commitment to transparency with a conference call and webcast for investors.

Negative

• None.

Conference Call and Webcast Scheduled for 1:30 p.m. PT

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2022 financial results after the market close on Wednesday, February 22, 2023. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 22, 2023.

A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. A replay will be archived on the company’s website following completion of the call.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005124/en/

Chris Lewis

Vice President, Investor Relations and Corporate Affairs

(949) 481-0510

clewis@glaukos.com

Source: Glaukos Corporation

FAQ

When will Glaukos release its Q4 and 2022 financial results?

Glaukos will release its fourth quarter and full year 2022 financial results after market close on February 22, 2023.

What time is the Glaukos conference call for the financial results?

The conference call will be held at 1:30 p.m. PT (4:30 p.m. ET) on February 22, 2023.

How can I access the Glaukos financial results webcast?

The live webcast will be available on Glaukos' investor relations website.

What is the focus of Glaukos Corporation?

Glaukos is focused on developing therapies for glaucoma, corneal disorders, and retinal diseases.